Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial

Elizabeth C. Smyth, Samuel Rowley, Fay H. Cafferty, William Allum, Heike I. Grabsch, Sally Stenning, Andrew Wotherspoon, Derek Alderson, Tom Crosby, Was Mansoor, Justin S. Waters, Helen Neville-Webbe, Suzanne Darby, Jo Dent, Matthew Seymour, Joyce Thompson, Sharmila Sothi, Jane Blazeby, Ruth E. Langley, David Cunningham*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1181-1187
Number of pages7
JournalJAMA Oncology
Volume5
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • GASTRIC-CANCER
  • HER2
  • ESOPHAGEAL

Cite this

Smyth, E. C., Rowley, S., Cafferty, F. H., Allum, W., Grabsch, H. I., Stenning, S., Wotherspoon, A., Alderson, D., Crosby, T., Mansoor, W., Waters, J. S., Neville-Webbe, H., Darby, S., Dent, J., Seymour, M., Thompson, J., Sothi, S., Blazeby, J., Langley, R. E., & Cunningham, D. (2019). Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 5(8), 1181-1187. https://doi.org/10.1001/jamaoncol.2019.1179